News Agency
The Times

VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism

  • Written by PR Newswire
  • 77.6% of patients treated with palopegteriparatide in the PaTHway China Trial achieved the primary multi-component endpoint compared to 0.0% for placebo (p <0.0001)
  •  Palopegteriparatide was generally safe and well-tolerated, with no discontinuations related to study drug.

SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- VISEN Pharmaceuticals, an...

Read more: VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide...

Why Shopify Web Development Is Important For Modern Online Stores

A successful online store requires more than attractive product images and basic functionality. Businesses need websites that load quickly, provide smooth navigation, and create a reliable shopping experience across all devices. Professional Shopify web development helps businesses build scalable eCommerce stores... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion